Toxic leadership
Real-world evidence on biologic use in paediatric asthma: there but not there yet?
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies
Role of Toxic Leaders in Shaping the Healthcare Providers' Engagement
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)
Prospective assessment of MR-guided single-fraction stereotactic ablative radiotherapy for peripheral lung metastases: dosimetric and clinical outcomes
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies